A study to characterize the phenotype in patients with Morton's Neuroma and to explore the effect of local administration of Xylocaine (lidocaine)
Study identifier:D2285M00032
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, double-blind, placebo-controlled, three-way cross-over single center study to characterize the phenotype in patients with Morton's Neuroma and to explore the effect of local administration of Xylocaine (lidocaine)
Medical condition
Morton's neuroma
Phase
N/A
Healthy volunteers
No
Study drug
Xylocaine, Placebo
Sex
All
Actual Enrollment
27
Study type
Interventional
Age
18 Years - 80 Years
Date
Study Start Date: 01 Feb 2011
Primary Completion Date: 01 May 2012
Study Completion Date: 01 May 2012
Study design
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Xylocaine_1mg 1 injection of Xylocaine (1 mg/mL) | Drug: Xylocaine 1 mg/mL solution for injection |
| Active Comparator: Xylocaine_10mg 1 injection of Xylocaine (10 mg/mL) | Drug: Xylocaine 10 mg/mL solution for injection |
| Placebo Comparator: Placebo 1 injection of placebo | Drug: Placebo solution for injection |
Contacts
Investigators
Principal Investigator
Bror Jonzon
AstraZeneca R&D Södertälje, Sweden
